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Treatment of Chronic Myeloid Leukaemia: 
Current Practice and Future Prospects 
Daniela M. Zisterer 
School of Biochemistry & Immunology, Trinity College Dublin 
Ireland 
1. Introduction 
Chronic myeloid leukaemia (CML) is a cancer of the hematopoietic system that arises from 
the Philadelphia chromosome (Ph1). This results from the reciprocal translocation of 
chromosomes 9 and 22 which generates a Bcr-Abl fusion gene encoding a 210kDa protein 
with constitutive tyrosine kinase activity (Ben-Neriah et al., 1986; Kuzrock et al., 1988). This 
constitutively active tyrosine kinase drives proliferation and survival through multiple 
downstream pathways (Reviewed in Cowan-Jacob et al., 2004; Ren et al., 2005). The disease 
is characterised by three stages; the chronic phase marked by an accumulation of mature 
granulocytes and myeloid precursors in the bone marrow and peripheral blood; the 
accelerated phase characterised by a rise in myeloid precursors and a blast crisis stage which 
is characterised by a marked accumulation of differentiation-arrested blast cells of either 
myeloid or lymphoid lineage (Calabretta & Perotti, 2004; Savage et al., 1997). The generation 
and clinical use of the Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate (IM) has 
revolutionised the treatment of CML patients (Druker et al., 1996; Druker et al., 2006) and 
has become the standard line of therapy for CML patients. Following treatment with 
imatinib, over 90% of patients obtain a complete haematologic response and more than 80% 
achieve a complete cytogenetic response. However, there are limitations associated with IM 
therapy. The drug is highly effective in the chronic phase of the disease but the response of 
patients in blast crisis is limited (Hehlman & Saussele, 2008). Furthermore, in approximately 
40% of patients, resistance develops i.e. resistance in 100 patient years (Gorre et al., 2001). 
Great progress has been made over the last ten years in elucidating the molecular 
mechanisms of IM-resistance in vitro but correlating any of these individual resistance 
mechanisms in a clinical sample does not always indicate that it alone drives clinical 
progression as additional modes of resistance may be at work. The mechanisms by which 
patients become resistant to IM therapy include Bcr-Abl dependent mechanisms such as an 
increase in the levels of Bcr-Abl mRNA expression and corresponding upregulation of 
protein levels and amplification of the Bcr-Abl gene (Mahon et al. 2000). Bcr-Abl 
independent mechanisms include activation of signalling pathways downstream of Bcr-Abl 
including the phosphatidylinositol 3-kinase (PI3K)/Akt cell survival pathway or activation 
of signalling pathways separate to that of the Bcr-Abl gene and an efflux of IM via multidrug 
resistant proteins such as p-glycoprotein (Capdeville et al., 2002). The most  
well-characterised cooperating pathway involves the Src Family Kinases (SFKs) which have 
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been demonstrated to play a role in altering responsiveness to TKIs as well as promoting 
disease progression (Danhauser-Riedl et al., 1996; Wilson et al., 2002). 
However, the major factor influencing IM resistance is due to mutations at critical points in 
the kinase domain of the Bcr-Abl gene which interferes with the ability of IM to interact with 
the enzyme. To date over 60 amino acid substitutions in the kinase domain have been found. 
Of these T315I is one of the most common Bcr-Abl mutations identified in patients and 
importantly this is also associated with the highest degree of IM-resistance, preventing the 
formation of the critical hydrogen bond and changing the conformation of the Bcr-Abl 
protein in such a way to render the protein completely resistant to imatinib. The frequency 
of the T315I mutation in IM-resistant patients is reported to range between 2% and 20% with 
variability related to detection methods along with patient cohort characteristics and 
treatment (Nicolini et al., 2009). Recent data suggests that the survival rate of patients 
harbouring a T315I mutation is dependent on disease phase at the time of mutation 
detection, with chronic phase patients responding to some investigational compounds 
(Nicolini et al., 2009). For example, Legros et al, (2007) reported T315I transcript 
disappearance in an IM-resistant CML patient treated with homoharringtonine and Giles et 
al, (2007) reported that 3 patients harbouring the T315I mutation achieved clinical responses 
with the aurora kinase inhibitor MK-0457. A greater understanding of the molecular basis of 
IM-resistance has provided the molecular rationale for the development of second and now 
third generation therapies for patients with CML. Such therapies will play a key role in the 
control of CML over the next decade. 
2. Second generation tyrosine kinase inhibitors 
Shortly after the introduction of IM in the clinic, reports of primary and secondary resistance 
cases began to emerge which led to the search for agents that might overcome this problem. 
The first second-generation TKI that was clinically evaluated was dasatinib (BMS-354825) 
and it was approved by the FDA for treatment of all phases of IM-resistant CML in June 
2006. Dasatinib is able to bind to both Bcr-Abl and Src family kinases and it was originally 
identified in a screen of compounds that demonstrated potent Src/Abl kinase inhibition 
with antiproliferative activity in CML cell lines and xenograft models systems (Lombardo et 
al., 2004). Nilotinib (AMN107) was subsequently developed by rational drug design based 
on the crystal structure of an Abl/imatinib complex, allowing researchers to optimise the 
potency and selectivity of the compound (Weisberg et al., 2005). 
Dasatinib and nilotinib were initially evaluated in patients with IM-resistant or intolerant 
CML. In phase II clinical trials with a 24 month follow up, both dasatinib and nilotinib were 
shown to have efficacy in patients in the chronic phase of CML (see Table 1). In the nilotinib 
trial, intolerance to imatinib was defined as having intolerance with no major cytogenetic 
response whereas in the dasatinib trial, imatinib-intolerant patients included patients who 
had a major cytogenetic response. These results were very promising and led to further 
Phase 3 trials where these second-generation TKIs were compared directly with imatinib as 
front-line therapies. It would be of interest in the future to determine the optimal time point 
for switching to second line treatment.  
Saglio et al., (2010), recently reported results from the Evaluating Nilotinib Efficacy and 
Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) trial. In this phase 3, 
randomized, multicenter study, 846 patients with chronic phase CML received either 
nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg 
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once daily). At 12 months, the rates of major molecular response for nilotinib (44% for the 
300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%). The 
rates of complete cytogenetic response by 12 months were significantly higher for nilotinib 
(80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%). Patients 
receiving nilotinib also had a significant improvement in the time to progression to the 
accelerated phase or blast crisis, as compared with those receiving imatinib. Based on these 
results the US FDA has granted accelerated approval of nilotinib for the treatment of 
patients with newly diagnosed CML in chronic phase. 
 
Response Dasatinib Nilotinib 
No. of patients 387 321 
Percent imatinib-resistant 74 70 
Percent imatinib-intolerant 26 30 
Percent CHR 91 95 
Percent McyR 62 59 
Percent CCyR 53 44 
Table 1. Summary of results of phase 2 studies of dasatinib and nilotinib in patients with 
chronic phase CML demonstrating either IM-resistance or intolerance. CHR. Complete 
hematologic response; McyR, major cytogenetic response; CCyR, complete cytogenetic 
response. 
Similarly, Kantarjian et al., (2010a) has reported the results of a trial comparing dasatinib 
versus imatinib in treatment naïve CML patients (DASISION trial). 519 patients with newly 
diagnosed chronic phase CML were randomly assigned to receive dasatinib at a dose of 100 
mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). After a 
follow-up of 12 months, the rate of complete cytogenetic response was higher with dasatinib 
than with imatinib (77% vs. 66%). The rate of major molecular response was higher with 
dasatinib than with imatinib (46% vs. 28%), and responses were achieved in a shorter time 
with dasatinib. Progression to the accelerated or blastic phase of CML occurred in 5 patients 
who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%) 
while the safety profiles of the two treatments were similar. These results also led to 
accelerated FDA approval in October 2010 for this second generation TKI for initial therapy 
of CML. Taken together, the results of these recent trials suggest that the best treatment for 
resistance may be preventing the emergence of resistance in the first place by using these 
alternative frontline therapies. In addition to second generation TKIs, modified imatinib-
based regimes (e.g. increasing the dose of imatinib to 800mg/day) are also currently under 
evaluation. It would also be of interest to determine whether administration of two or more 
TKIs together or consecutively would improve disease control as compared to single-agent 
therapy but such a course of study would present many difficulties in terms of clinical trial 
design.  
3. Combination approaches and investigational compounds  
The currently available TKIs do not demonstrate efficacy against the T315I mutation 
suggesting the need for additional strategies such as combination approaches with 
alternative classes of agents. Prior to the introduction of imatinib, interferon (IFN) alpha-
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based regimens were the gold standard for treatment of early chronic phase CML patients. 
The combination of IFN-alpha with imatinib was recently investigated in two large clinical 
trials, the French SPIRIT trial and the German CML Study IV. In the SPIRIT trial 636 patients 
were randomised 1:1:1:1 to receive either imatinib 400mg/day, 600mg/day, 400mg/day 
plus cytarabine or 400mg/day plus INF-alpha. After 18 months MMR rates were 41% versus 
52% versus 53% versus 62% respectively (Preudhomme et al., 2010). In the German study 
CML IV, patients were given imaitinib 400mg/day versus 800mg/day versus 400mg/day 
plus IFN-alpha. Response rates were higher in the imatinib (800mg/day) cohort (CCyR 65%, 
MMR 54%) when compared to the imatinib (400mg/day) cohort with or without IFN-alpha 
(CCyR 52% and 51%; MMR 30% and 35%, respectively) suggesting in this case that high 
dose imatinib increases the rate of MMR at 12 months (Hehlmann et al., 2011). Furthermore, 
they demonstrated that achievement of MMR by month 12 is directly associated with 
improved survival (Hehlmann et al., 2011). 
A number of investigational compounds, many of which are active against T315I mutants 
have also been identified and many are currently undergoing clinical trials and are 
summarised in Table 2. These can be subdivided into four classes; third generation TKIs, 
aurora kinase inhibitors, switch pocket inhibitors and apoptosis modulators.  
3.1 Third generation TKIs 
Despite the very promising results with dasatinib and nilotinib there is still room for 
improvement. Due to the fact that the currently available TKIs have no activity against T315I 
mutants, many investigational compounds are currently being clinically evaluated in this 
cohort of patients. Ponatinib (AP24534) is an orally bioavailable multi-targeted compound 
with activity against many kinases including native Bcr-Abl, the T315I mutant and other 
mutants (O’Hare et al., 2009). Ponatinib does not need to make a hydrogen bond with T315 
therefore it can accommodate the side chain of the isoleucine residue in the T315I mutation 
(O’Hare et al., 2009). In kinase-based assays, ponatinib potently inhibited the activity of 
wild-type Bcr-Abl and the T315I mutant in the nanomolar range. Ponatinib also exhibited 
nanomolar activity against other kinases such as SRC, FGFR1, FLT3, KIT and VEGFR. A 
phase I trial of ponatinib has recently been completed and a phase II trial is currently 
underway. If ponatinib can be demonstrated to be a pan-Bcr-Abl inhibitor in the clinic and it 
is proven to be safe and effective it may be a future frontline therapeutic for CML. 
Bosutinib, is a third generation TKI that is currently being developed by Pfizer. It inhibits 
Bcr-Abl with higher potency than imatinib but it also demonstrates activity against a 
number of other kinases including SFKs, c-Kit and PDGF receptors (Remsing-Rixet et al., 
2009). Bosutinib is currently undergoing frontline testing against imatinib with promising 
results. This third generation TKI may shortly win FDA approval for initial therapy of CML 
(Bixby & Talpaz, 2011).  
INNO-406 is an orally bioavailable dual Abl/Lyn kinase inhibitor which is up to 50 times 
more potent than imatinib against Bcr-Abl. Results of a Phase I trial with this TKI have 
recently been reported (Kantarjian et al., 2010b). INNO-406 was administered to 56 patients 
with imatinib resistance (n = 40) or intolerance (n = 16). Other previous treatments included 
nilotinib (n = 20 patients), dasatinib (n = 26 patients), and dasatinib/nilotinib (n = 9 
patients). Of 31 patients with CML in chronic phase who received INNO-406, the major 
cytogenetic response rate was 19%. No responses were observed in patients who had CML 
in accelerated phase or in blastic phase. The maximium tolerated dose was identified at 
240mg twice daily and further phase II studies are planned.  
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XL228 is an intravenously available multi-targeted TKI that has significant in vitro activity 
against the T315I mutant. It is currently been investigated in a small clinical trial of 27 
patients where 20 of the patients harbour the highly resistant T315I (10 patients), F317L (7 
patients) and V299L (3 patients) mutations. Preliminary clinical activity has been reported in 
a poster session at the 50th Annual American Society of Haematology in December 2008 
(Abstract 3232) and looks promising. XL228 is being currently tested in two Phase I clinical 
trials, one for the treatment of CML or Ph+ acute lymphoblastic leukaemia (ALL), and the 
second for the treatment of advanced malignancies including lymphoma.  
3.2 Aurora kinase inhibitors 
Aurora kinases A and B are a group of serine/threonine kinases also known as mitotic 
kinases, that regulate the transition from G2 through cytokinesis. Aurora kinases are 
overexpressed in several types of solid tumours and some haematological malignancies 
including acute myeloid leukaemia (AML) (Ye et al., 2009). Inhibition of these kinases in 
leukaemia cells has been shown to result in aberrant mitosis which in turn can lead to 
mitotic catastrophe. Aurora kinase inhibitors are being developed as potential targeted 
therapies for cancer patients. There is much similarity between the ATP binding sites of 
aurora kinases and other kinases including Bcr-Abl.  
Danusertib is an intravenously administered multi-targeted kinase inhibitor which 
demonstrates significant activity against various aurora kinases (Gontarewicz & 
Brummendorf, 2010). It has also demonstrated in vitro efficacy against native Bcr-Abl and 
the T315I mutant. A phase I clinical trial is currently underway with advanced phase CML 
patients resistant or intolerant to imatinib and/or a second generation TKI. 
AT9283 is an Aurora kinase A and B inhibitor which is administered intravenously. It 
exhibits efficacy in the nanomolar range against Abl and the T315I mutant along with a 
range of other kinases including JAK 2 and 3 and FGF4 (Howard et al., 2009). Phase I trials 
are currently underway in the United States. 
One potential problem associated with aurora kinase inhibitors is that they all require 
prolonged intravenous administration and response have frequently been associated with 
the periods at which the drug is administered. 
3.3 Switch pocket inhibitors 
Recently a series of non-ATP competitive multi-kinase inhibitors have been developed. 
Switch pocket inhibitors bind to amino acid residues that kinases use to undergo the 
conformational change from the inactive(closed) to the active(open) state and therefore they 
keep the kinase in the inactive conformation (Chan et al., 2011; Eide et al., 2011). An 
important structural feature of the Abl kinase is the presence of a series of hydrophobic 
residues that are stacked in a layer and help to stabilise the active conformation. Indeed the 
T315I mutant further stabilises the active conformation possibly leading to increased activity 
of the enzyme. DCC-2036 is one of the lead switch pocket inhibitors. It is an orally 
bioavailable compound that has demonstrated activity against both native Abl and the 
T315I mutant and a number of other kinases such as VEGFR2 (Chan et al., 2011; Eide et al., 
2011). The compound is currently been evaluated in a phase 1 clinical trial for use in 
imatinib-resistant CML including patients with T315I mutation. 
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3.4 Apoptosis modulators 
Certain compounds that function independently of kinase inhibition activity are also being 
developed. Omacetaxine is one such compound. Omacetaxine is a semisynthetic 
formulation of the alkaloid homoharringtone which can be administered subcutaneously. 
Homoharringtone has been shown to exhibit anti-tumoural effects by disrupting protein 
synthesis and downregulating the anti-apoptotic protein myeloid cell leukaemia-1 (MCL-1) 
(Tang et al., 2006). This leads to disruption of the mitochondrial membrane with release of 
cytochrome c, caspase activation resulting in apoptotic cell death (Tang et al., 2006). 
Omacetaxine is currently been evaluated in two multicentre Phase III clinical trials for 
patients with CML who have failed two or more TKIs or for patients with the T315I 
mutation. It may become the first drug to be approved for third-line therapy in CML. 
 
Drug Class Company Targets Activity 
against T315I 
mutant 
References 
TKIs 
Ponatinib Ariad U.S.A. 
 
ABL, FGFR1, 
FLT3, KIT, VEGFR
Yes O’Hare et al., 2009 
Bosutinib  
 
Pfizer U.S.A. 
 
ABL,CAMK2G, 
STE20, TEC 
No Bixby & Talpaz, 
2011; Remsing Rix 
et al., 2009  
INNO-406 
 
CytRx U.S.A 
 
ABL, KIT, LYN, 
PDGFR 
No Kantarjian et al., 
2010b 
XL228 Exelixis U.S.A ABL, Aurora A, 
FGFR1-3, IGF1R, 
SRC 
Yes Not applicable 
Aurora kinase inhibitors 
AT9283 Astex, U.K. ABL, Aurora A & 
B, FLT3, JAK2, 
JAK3 
Yes Howard et al., 
2009 
Danusertib Nerivano 
medical sciences, 
Italy 
ABL, Aurora A & 
B,FGFR1, RET, 
TRK 
Yes Gontarewicz & 
Brummendorf , 
2010 
Switch pocket inhibitors 
DCC-2036 Deciphera, U.S.A. ABL, FLT3, KDR, 
SFK, TIE2 
Yes Chan et al., 2011; 
Eide et al., 2011 
Apoptosis modulators 
Omacetaxine ChemGenex, 
Australia 
Cytochrome c, 
MCL-1 
Yes Tang et al., 2006 
Hsp90 inhibitor 
KOS-1022 
Kosan, U.S.A. Cytochrome c Yes Gorre et al., 2002 
Table 2. Investigational compounds in chronic myeloid leukaemia 
Heat shock protein 90 (Hsp90) is a chaperone protein that assists client proteins in folding 
and prevents protein misfolding and degradation by the proteasome. The Hsp90 antagonist, 
17-allyamino-17-demethoxygeldanamycin (17-AAG), has been shown to cause release of 
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cytochrome c, caspase activation and apoptosis in native Bcr-Abl cells and those expressing 
the T315I mutant (Gorre et al., 2002). Clinical trials with the more soluble analogue of 17-
AAG, 17-DMAG (KOS-1022) are currently ongoing. 
Our group have recently reported the effects of representative members of the novel pro-
apoptotic microtubule depolymerising pyrrolo-1,5-benzoxazepines or PBOX compounds on 
chemotherapy-refractory CML cells using a series of Bcr-Abl mutant cell lines, clinical ex 
vivo patient samples and an in vivo mouse model (Bright et al., 2010). The PBOX compounds 
potently reduced cell viability in cells expressing the E225K and H396P mutants as well as 
the highly resistant T315I mutant. The PBOX compounds also induced apoptosis in primary 
CML samples including those resistant to imatinib. In addition we have shown that the 
PBOXs enhance the apoptotic efficacy of imatinib in CML cell lines (Bright et al., 2009; 
Greene et al., 2007). Furthermore we have demonstrated the in vivo efficacy of a 
representative pro-apoptotic PBOX compound, PBOX-6, in a CML mouse model of the 
T315I Bcr-Abl mutant. Results from this study highlight the potential of these novel series of 
PBOX compounds as potential therapy against CML. 
4. Stem cell transplantation 
Prior to the advent of imatinib and other TKIs, allogeneic hematopoietic stem cell 
transplantation (HSCT) was the main therapeutic option for CML patients and indeed is the 
only known curative treatment for CML to date. After the initial results with imatinib were 
published, allogeneic transplantation began to decline as a frontline treatment for CML. 
However to date there is no prospective study that compares imatinib and HSCT as 
frontline treatments. A retrospective review of over 1000 patients who received an 
allogeneic transplant in the pre-imatinib era reported an overall survival rate of 47% after 8 
years and a relapse rate of 33% after 5 years (Gratwohl et al., 1993). More recently, Saussele 
et al., reported the results of an analysis of a subgroup of the randomized German CML 
study IV. These patients received a transplant after imatinib failure and demonstrated a 91% 
survival after 3 years (Saussele et al., 2010). Imatinib does not appear to impair engraftment 
and the incidence of graft versus host disease and survival was the same as for patients in 
the same stage of the disease who were not treated with imatinib. Since TKIs have no 
harmful effect on the transplant outcome they can be used until a suitable donor is found 
and the transplant procedure is performed. On the recommendation of the European 
LeukemiaNet, allogeneic transplant is now considered for those patients who have failed 
treatment with a second-generation TKI, patients in the advanced or blastic phase of CML at 
the time of diagnosis (as these patients are not responsive to TKIs) or those with the T315I 
mutation (see Table 3). Transplantation may also be an option for those patients that 
develop mutations while undergoing second line therapy (Baccarani et al., 2009). Finally 
transplantation may possibly be an option for pediatric or young patients with a suitable 
donor as the long term effects of TKIs such as drug toxicity (Kerkala et al., 2006) and 
immune dysfunction (Dietz et al., 2004) have not been clearly identified to date. Finally the 
capacity to combine novel TKIs with allogeneic transplantation in high-risk patients will 
potentially improve survival but further studies are required. Unfortunately only a low 
percentage of patients receive a transplant for a variety of reasons such as age and lack of 
appropriate donors. In the German CML study IV, of the 1,242 CML patients involved, 84 
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patients underwent allogeneic HSCT, with a relatively young age of patients reported 
(median age of 36 years) (Saussele et al., 2010).  
 
Chronic phase, frontline therapy Imatinib (400mg daily) 
Chronic phase, second-line therapy 
IM-intolerance 
IM-failure 
Nilotinib (400mg twice daily) or Dasatinib 
(100mg daily) 
Nilotinib (400mg twice daily) or Dasatinib 
(100mg daily) or HSCT in low 
transplantation risk and high risk disease 
(e.g. T315I mutation) 
Chronic Phase, third-line therapy 
In case of dasatinib or nilotinib failure 
HSCT 
Accelerated and blastic phase 
Frontline 
Second-line 
Imatinib followed by HSCT wherever 
possible 
Nilotinib or Dasatinib followed by HSCT 
wherever possible 
Table 3. Current recommendations for treatment of CML patients (modified from Baccarani 
et al., 2009) 
5. Chronic myeloid leukaemia stem cells 
There is also a mounting body of evidence suggesting that in many cancers, including CML, 
cancer stem cells (CSCs) evolve as a result of both genetic and epigenetic events that alter 
hematopoietic progenitor differentiation, survival and self-renewal. Hematopoietic stem 
cells (HSCs) are defined by their capacity for self-renewal and their ability to give rise to all 
mature haematopoietic cell lineages throughout an individual’s lifetime. There is 
accumulating evidence to suggest that CML cells emerge due to expression of Bcr-Abl in 
normal HSCs. Transplantation of multipotent murine HSCs expressing Bcr-Abl into 
recipient mice induces a CML-like myeloproliferative disorder (Pear et al., 1998) whereas 
CML is not induced in committed murine haematopoietic progenitor cells expressing Bcr-
Abl (Huntly et al., 2004). There is also accumulating evidence that the signalling pathways 
that control normal HSC fate also determine maintenance of stem cell function. Recently 
signalling pathways or molecules such as Wnt/-catenin, hedgehog (Hh), promyelocytic 
leukaemia (PML) and forkhead box class O of transcription factors (FOXO) have been 
shown to control stem cell fate in both normal hematopoiesis and in CML. 
5.1 Signalling pathways underlying maintenance of CML stem cells  
The wnt/-catenin signalling pathway is thought to play a role in maintenance of CML stem 
cells. There are numerous reports demonstrating that -catenin regulates normal mouse 
HSC renewal (Reya et al., 2003; Zhao et al., 2007). Furthermore, Zhao et al., 2007 performed 
a series of mouse genetic studies demonstrating that conditional deletion of -catenin 
reduced maintenance of CML stem cells in the chronic phase. Loss of -catenin also 
suppressed infiltration of CML cells into the lung and liver of mice injected with CML stem 
cells (Zhao et al., 2007).  
The hedgehog signalling pathway is also though to underlie stem cell fate in both normal 
hematopoiesis and CML. In the absence of Hh ligands, Patched (Ptch) a twelve-
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transmembrane receptor inhibits smo, a seven-transmembrane receptor. The binding of Hh 
ligands such as Indian hedgehog, Desert hedgehog or Sonic hedgehog to the Patched 
receptor in turn activates Smo and this receptor activates downstream signalling events 
mediated through activation of Gli transcriptional effectors. Two recent studies have 
demonstrated that expansion of Bcr-Abl leukaemic stem cells is dependent on the hedgehog 
pathway. Conditional Smo deletion caused CML stem cell suppression and impaired CML 
progression (Dierks et al., 2008; Zhao et al., 2009). Furthermore expression of constitutively 
active Smo increased the frequency of CML stem cells and accelerated CML development 
(Zhao et al., 2009) demonstrating an essential requirement for the Hh signalling pathway in 
maintenance of CML stem cells.  
The promyelocytic leukaemia (PML) protein is a tumour suppressor protein localising to 
PML nuclear bodies. It plays a role in a wide array of biological activities including 
apoptosis, senescence and the DNA damage response pathway. Ito et al., 2008 reported high 
expression of PML in normal HSCs and demonstrated that conditional deletion of Pml 
resulted in intensive cell cycling which in turn resulted in impaired self-renewal capacity. 
They also demonstrated the defective ability of Pml-/- CML stem cells to develop CML at the 
3rd serial transplantation.  
Forkhead box class O of transcription factors (FOXO) have been shown to control stem cell 
fate in both normal hematopoiesis and in CML. The FOXO family of transcription factors 
include FOXO1, FOXO3a, FOXO4 and FOXO6 and they are all downstream targets of the 
cell survival phosphatidylinositol-3-kinase-AKT signalling pathway. When a ligand such as 
a growth factor or insulin binds to its receptor and activates the PI3-K-AKT pathway, AKT 
phosporylates FOXOs preventing their translocation to the nucleus and causing their 
degradation. It is widely believed that Bcr-Abl activates AKT signalling and suppresses 
FOXOs which in turn enhances the proliferation or inhibits the apoptosis of CML cells. 
However, Naka et al., (2010) have recently shown that FOXO3a plays an essential role in the 
maintenance of CML stem cells through the use of a syngeneic transplantation system and a 
CML-like myeloproliferative disease mouse model. They demonstrated that cells with a 
nuclear localisation of FOXO3a and decreased AKT phosphorylation are enriched in CML 
stem cell population, despite expression of Bcr-Abl. They also found that the ability of CML 
stem cells to promote malignancy at the 3rd transplantation is significantly decreased by 
Foxo3a deficiency in vivo. In addition, they have shown that TGF-beta is a critical regulator 
of AKT activation in CML stem cells and control the localisation of FOXO3a. This suggests 
the potential of TGF-beta-FOXO signalling inhibitors in eradicating CML stem cells.  
The transcription factor JunB has been shown to protect against myeloid malignancies 
including CML by limiting hematopoietic stem cell proliferation and differentiation. 
Inactivation of JunB deregulates the cell-cycle machinery and increases the proliferation of 
HSCs without impairing their self-renewal or regenerative potential in vivo (Santaguida et 
al., 2009). Such data increases our understanding of how defects in signalling pathways that 
control the proliferation of stem cells leads to an increase in their transformation ability. 
5.2 Mechanisms of tyrosine kinase inhibitor resistance of CML stem cells 
Many studies have shown that TKIs such as imatinib, dasatinib and nilotinib potently 
inhibit TKI in differentiated CML stem cells but are not as effective in quiescent CML stem 
cells. For example, the presence of detectable primitive leukaemic progenitor cells in CML 
patients with an established complete cytogenetic response after 5 years on imatinib 
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treatment has been demonstrated (Bhatia et al., 2003). Furthermore, patients with an 
apparent molecular remission of CML following cessation of imatinib treatment quickly 
relapse (Cortes et al., 2004). It has been suggested therefore that these quiescent stem cells 
may be a reservoir for relapse (Holyoake, 1999; Wang et al., 1998). Drugs that are capable of 
eradicating the CML stem cells would provide much improved treatment for CML patients. 
To date, a number of potential mechanisms mediating TKI-resistance of CML stem cells 
have been postulated.  
Firstly FOXO has been suggested to contribute to resistance to TKI therapy. Komatsu et al., 
(2003), has previously reported that FOXO3a is a downstream effector of imatinib induced 
cell cycle arrest in Bcr-Abl expressing cells and that FOXO inactivation sensitises cells to 
imatinib treatment suggesting that FOXO contributes to resistance to TKI treatment. To 
study this further in CML stem cells, Naka et al., (2010) investigated the roles of Foxo3a in 
response to TKI therapy using a CML mouse model. They showed that Foxo3a deficiency 
sensitised CML stem cells to TKI treatment and suggested that Foxo3a plays diverse roles in 
CML stem cell and non-stem cells. In their model, FOXO activation protects CML stem cells 
against TKI treatment while in non-CML stem cells it induces apoptosis or cell cycle arrest. 
In this same paper, they provided both in vitro and in vivo data which demonstrates a role 
for the TGF-beta/FOXO signalling pathway in maintaining imatinib-resistant CML stem 
cells. Treatment of CML stem cells with a TGF-beta inhibitor, Ly364947, impaired their 
colony forming ability in vitro and a combination of TGF-beta inhibition, Foxo3a deficiency 
and imatinib treatment resulted in efficient depletion of CML in vivo. Thus inhibition of 
TGF-beta signalling may result in eradication of the reservoir of CML stem cells. 
There have also been recent reports demonstrating that Bcr-Abl stimulates the proteasome 
mediated degradation of certain FOXO family members in an animal model and in samples 
taken from CML patients (Jagani et al., 2009). Treatment with the proteasome inhibitor, 
bortezomib, resulted in an inhibition of Bcr-Abl mediated downregulation of FOXO and a 
regression of leukaemia suggesting that bortezomib is a candidate therapeutic in the 
treatment of Bcr-Abl-induced leukaemia. Furthermore, recent data demonstrate that 
bortezomib has significant activity against CML stem cells and synergises with imatinib in a 
CML murine model (Heaney et al., 2010; Hu et al., 2009). Bortezomib has also been shown to 
inhibit proteosomal degradation of protein phosphatase 2A (PP2A). This in turn reactivates 
PP2A which is an important negative regulator of Bcr-Abl (Hu et al., 2009). However, due to 
the known toxicities of bortezomib, including myelosuppression, the likely initial clinical 
application of bortezomib in CML would be in resistant and advanced disease. 
Other work has demonstrated that Hh signalling contributes to TKI resistance. Dierks et al., 
(2008) demonstrated that inhibition of the Hh signalling pathway with cyclopamine, which 
maintains Smo in its inactive form, impairs development of CML by CML stem cells. In 
addition, a combination of cyclopamine with nilotinib delayed the recurrence of the disease 
compared to treatment with nilotinib alone (Dierks et al., 2008).  
Another key molecule that may control TKI resistance of CML stem cells is reported to be 
the arachidonate 5-lipoxygenase (Alox5) gene which encodes a lipoxygenase 5-LO (Chen et 
al., 2009). Gene expression profiling demonstrated that Alox5 expression is up-regulated by 
Bcr-Abl. In the absence of Alox5, Bcr-Abl failed to induce CML in mice. This Alox5 
deficiency caused impairment of the function of CML stem cells but not normal 
hematopoietic stem cells by affecting their differentiation and cell division. This in turn 
caused a depletion of CML stem cells and a failure of CML development. Treatment of CML 
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mice with a 5-LO inhibitor, zileuton, also impaired the function of CML stem cells and 
prolonged survival of CML affected mice. These results demonstrate that a specific target 
gene can be found in CML stem cells and its inhibition can inhibit the function of these stem 
cells. It is of interest to note that upregulation of Alox5 was not inhibited by treatment with 
TKIs which may go some way to explaining why imatinib does not affect CML stem cells. 
PML as described above is also an important target of CML stem cell therapy. Ito et al., 
(2008) demonstrated the critical role of this tumour suppressor in CML stem cell 
maintenance, and presented a new therapeutic approach for targeting quiescent CML stem 
cells by pharmacological inhibition of PML. Treatment of mice with arsenic trioxide, which 
downregulates PML expression, completely eradicated CML stem cells when used in 
combination with the chemotherapeutic drug Ara-C. This suggests that targeting PML for 
degradation could be an attractive therapeutic approach for targeting CML stem cells. 
Autophagy is a genetically controlled process whereby organelles and long lived proteins 
are sequestered and engulfed into vacuoles called autophagosomes. These autophagosomes 
then fuse with lysosomes to produce autolysosomes which are targeted for either 
destruction or recycling (Kroemer & Levine, 2008). In certain situations autophagy serves as 
an alternative to apoptosis and is thus called type II cell death whereas in other cellular 
contexts, such as starvation induced by growth factor withdrawal/metabolic stress, it serves 
as a cell survival mechanism allowing tumour cells to become metabolically dormant. It has 
recently been reported that imatinib not only induces apoptotic cell death in CML cells but 
also induces autophagy following the induction of ER stress (Bellodi et al., 2009). In 
addition, inhibition of autophagic cell death using pharmacological inhibitors of 
autophagosome-lysosome fusion (chloroquine and bafilomycin) enhanced imatinib-induced 
cell death in CML cell lines and primary CML cells including those expressing partially IM-
resistant Bcr-Abl mutants. Furthermore and of even greater importance, CML stem cells 
were shown to be extremely sensitive to the combination treatment. Knockdown of the 
autophagy genes Atg5 and Atg7 in CML cells also enhanced TKI-induced cell death. These 
workers therefore postulated that TKI-induced autophagy may antagonise TKI-induced cell 
death through apoptosis and inhibition of autophagy may eliminate this survival 
mechanism by restoring sensitivity of CML stem cells to TKI therapy (Bellodi et al., 2009). 
This approach would avoid the necessity of targeting CML stem cells through Bcr-Abl-
indpendent approaches. In addition normal stem cells would not be targeted as these 
autophagic inhibitors had little or no effect on normal progenitors. The results of the Bellodi 
study have recently led to a randomised phase II clinical trial of IM versus 
IM/hydrochloroquine in CML patients which is being initiated at a number of centres in the 
U.K. This is known as the CHOICES (chloroquine and imatinib combination to eliminate 
stem cells) trial. 
Histone deacetylase inhibitors (HDACIs) are drugs that target histone deacetylase 
complexes which modulate chromatin acetylation resulting in changes in gene expression. 
These inhibitors have a wide variety of effects as they also inhibit deacetylation of 
chaperone proteins such as Hsp90, transcription factors and a variety of other signalling 
mediators. It has previously been shown that treatment of CML cells with HDACIs such as 
LBH589 resulted in a downregulation of Bcr-Abl and an induction of apoptosis (Fiskus et al., 
2006). In addition synergistic effects were observed with HDACIs in combination with a 
variety of TKIs (dasatinib, nilotinib and imatinib). The HDACIs are thought to target Hsp90 
which results in decreased chaperone activity of Hsp90 leading to increased proteosomal 
degradation of Bcr-Abl. A recent report has demonstrated that the HDACI LBH589 when 
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used in combination with imatinib induced apoptosis of quiescent CML stem cells with a 
subsequent lack of engraftment in immunodeficient mice (Zhang et al., 2010). Thus a further 
possibility for eradication of CML stem cells may lie in combining TKIs with HDACIs. 
Table 4 below summarises the key signalling pathways/molecules that are thought to play a 
role in mediating resistance to TKI therapy and drugs that target these pathways/molecules 
that may have potential either alone or in combination for CML therapy.  
 
Drug Drug target in CML 
stem cells 
Combination therapy Reference 
Ly364947 
 
TGF-beta-FOXO  
signalling pathway 
 
Ly364947 and imatinib  
improved survival of CML 
mice 
Komatso et al., 
2003 
Cyclopamine Smo in the hedgehog  
signalling pathway 
Cyclopamine and nilotinib 
 improved survival of 
CML mice 
Dierks et al., 
2008 
Zileuton 5-lipoxygenase Zileuton and imatinib 
 prolonged survival of 
CML mice 
Chen et al., 
2009 
Arsenic trioxide PML Arsenic trioxide and AraC  
prolonged survival of 
CML mice 
Ito et al., 2008 
Chloroquine  
 
Autophagy  Chloroquine sensitised 
primary 
 CML stem cells to 
imatinib-induced  
cell death 
Bellodi et al., 
2009 
LBH589 HDACs LBH589 and imatinib co-
treatment  
induced apoptosis of CML 
stem 
 cells and prevented  
subsequent engraftment in 
immunodeficient mice 
Zhang et al., 
2010 
Table 4. Signalling pathway/key molecules underlying TKI-resistance in CML stem cells as 
potential drug targets 
6. Immunotherapy for the treatment of CML 
Clinical interest in immunotherapy still remains as allogeneic stem cell transplantation, 
which relys on a graft versus leukaemia effect, provides the only long-term eradication of 
CML. The differences in minor histocompatibility antigens between recipient and donor 
along with effector cells specifically targeted at leukaemic antigens contributes to the cure 
of the disease (Rezvani & Barret., 2008). Additional evidence that CML is a disease 
susceptible to immunotherapy is provided by reports demonstrating the benefit of 
allogeneic donor lymphocyte infusions following transplantation (Drobyski & Keever, 
1993; Kolb et al., 1995).  
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As mentioned above, CML is a clonal disorder of pluripotent haematopoietic stem cells 
which is characterised by the Bcr-Abl fusion protein. This results from the reciprocal 
translocation of chromosomes 9 and 22 which generates a Bcr-Abl fusion gene (Ben-Neriah 
et al., 1986). The t(9;22) mRNA is translated to a chimeric Bcr-Abl protein of molecular 
weight 210kDa often referred to as the p210 protein. However different breakpoint areas in 
the bcr gene have been identified resulting in slight variations in fusion transcripts. The 
most commonly expressed transcripts are the b3a2 and b2a2 transcripts (Deininger & 
Goldman, 2000). This generates a neo-antigen which is tumour specific because it contains a 
new sequence of amino acids in the junctional region of p210 that are not present in normal 
hematopoietic stem cells. This in turn provides a unique target for immunotherapeutic 
intervention using a vaccine-based approach.  
6.1 Antigen-specific targets in CML-Bcr-Abl junctional peptides 
The junctional regions of p210 contain not only a unique sequence of amino acids but 
additionally a new amino acid is formed due to codon split during translocation. Thus a 
lysine in b3a2 and a glutamic acid in b2a2 is generated (Shtivelman et al., 2006). There have 
been many reports of immunogenicity of the fusion region derived peptides of p210 with 
respect to the major histocompatibility complex (MHC) class I and II. For example, the 
p210/b3a2-derived fusion protein amino acid sequences have been shown to bind to various 
class I HLA antigen molecules including A0201, A3, A11 and B8 (Berke et al., 2000) 
supporting the potential of these peptides as target for class I HLA-restricted T-cell 
cytotoxicity. However, presentation of other Bcr-Abl junctional peptides has not been 
established in other HLA types which somewhat limits the clinical potential of class I 
peptides to subpopulations with specific HLA alleles. Strategies have been implemented to 
improve the binding of HLA class I molecules by amino acid substitutions at key binding 
residues of Bcr-Abl peptides to try and overcome their somewhat poor immunogenicity 
(Pinilla-Ibarz et al., 2005). Interest has also developed in class II Bcr-Abl specific peptides 
although less is known regarding the interaction of Bcr-Abl peptides with HLA class II 
molecules (Mannering et al., 1997; Yasukawaet al., 1998). In addition several clinical trials 
have been initiated using peptide based vaccines to treat CML, often with concomitant 
treatment of interferon-alpha or imatinib (Bocchia et al., 2005; Cathcart et al., 2004; Pinilla-
Ibarz et al., 2000; Rojas et al., 2007). Results of these trials are reviewed by Pinilla-Ibarz et al., 
(2009).  
6.2 Selectively expressed and over-expressed antigens in CML 
Another potential target for immunotherapy are antigens that are selectively expressed or 
over-expressed. Wilms’ tumour antigen 1 (WT1) is a transcription factor that is over-
expressed in many human leukaemias including CML and also in solid malignancies and 
several class I restricted epitopes have been identified to date (Ariyaratana & Loeb, 2007). 
The expression of WT1 in CML has been shown to correlate with disease progression. Many 
peptides have been designed and cytotoxic T-lymphocytes generated in the presence of 
some of these peptides were able to specifically target WT1-expressing leukemic cells while 
sparing normal progenitors (Oka et al., 2000).  
The efficacy of WT1-based vaccines has been the study of a number of trials with patients 
with AML, breast cancer, lung cancer, myelodysplastic syndrome and mesothelioma with 
promising results (Chaise et al., 2008; Li Z et al., 2005; Oka et al., 2004).  
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Another promising target in immunotherapy is PR3, a serine protease which is stored in 
neutrophils and is over-expressed in 75% of CML patients. CD8+ T cells specific for PR3 
have been identified in patients in remission following HSCT and correlated with 
cytogenetic remission (Moldrem et al., 2006). 
Several other antigens have been reported as being over-expressed in CML including 
preferentially expressed antigen of melanoma (PRAME) (Rezvani et al., 2009) and human 
telomerase reverse transcriptase (hTERT) (Gannage et al., 2005) and these may also be useful 
for immunotherapy in leukaemia.  
It is also important to note the differential and sequential expression of several tumour 
antigens in different phases of CML suggesting the importance of combining several 
antigens in the design of future vaccines. The safety and immunogenicity of a combined 
vaccine of two antigenic peptides, PR1 and WT1, has recently been described and supports 
further studies of immunisation strategies in CML patients (Rezvani et al., 2008).  
6.3 Immunomodulatory effects of TKIs 
It has been hypothesised that imatinib reduces the efficacy of graft versus leukemia effect or 
other T-cell-based immunotherapies. This is based on several studies reporting impaired T-
cell specific proliferation and responses as well as the inhibition of antigen-specific memory 
T cells (Boissel et al., 2006; Mumprecht et al., 2006). Conversely, imatinib has also been 
demonstrated to initiate an increase in IFN-gamma-producing T cells following 3 months of 
treatment and it may restore the function of Th1 helper T cells (Aswald et al., 2002).  
In vivo antitumour T-cell immunity has been observed in several clinical trials using both 
Bcr-Abl peptide vaccines and other cellular vaccines (Maslak et al., 2008 & Smith et al., 
2006). The use of imatinib in conjunction with donor lymphocyte infusion for relapsed CML 
patients following HSCT has also been shown to be efficacious suggesting that the clinical 
effect of imatinib may actually be beneficial (Olavarria et al., 2007; Savani et al., 2005). 
Second generation TKIs have also been shown to have immunomodulatory effects. For 
example, nilotinib has been shown to inhibit the expansion of CD8+ T lymphocytes specific 
for viral or leukemia antigens much more potently that the same inhibitory effect elicited by 
imatinib. These effects are thought to mediated through inhibition of phosphorylation of the 
Src family kinase Lck (Blake et al., 2008). Furthermore, dasatinib was found to inhibit T-cell 
receptor mediated signal transduction, cytokine production and in vivo T cell responses 
(Blake et al., 2008; Fei et al., 2008). Again the effect is thought to be mediated by the 
inhibition of Lck.  
7. New application of old therapies 
Interferon was the most efficacious drug in the treatment of patients in the chronic phase of 
the disease prior to the advent of TKIs. There is now evidence that interferon-alpha may 
interfere with stem cell retention in the microenvironment and that it activates dormant 
haematopoietic stem cells (Essers et al., 2009). In response to treatment of mice with 
interferon-alpha, HSCs efficiently exited the dormant G(o) and entered an active cell cycle. 
In addition, HSCs pretreated with interferon-alpha were eliminated by 5-fluorouracil 
treatment, which raises the possibility for new applications of type I interferons to target 
CML stem cells. Two large randomized studies show improved outcome when pegylated 
IFN-alpha is combined with imatinib (Hughes et al., 2010). It could be suggested that IFN-
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alpha stimulates the quiescent stem cells to proliferate thereby increasing sensitivity to 
imatinib. Although imatinib and other TKIs are very efficient, they are rarely curative. IFN-
alpha could be included in combination treatment protocols aimed at curing patients and 
thus could still be an important drug in CML treatment. 
8. Concluding remarks 
The understanding of the biology underlying CML has rapidly advanced in the last fifty 
years. From initially identifying a cytogenetic abnormality, we have gone on to translating 
this finding into treatment strategies for this disease. Imatinib has revolutionised the 
treatment of CML and for patients who fail this treatment, nilotinib and dasatinib may 
reduce the rate of progression of the disease. Indeed some of these second generation 
tyrosine kinase inhibitors may represent a better first-line treatment option for some patients 
with possible benefits including an improvement in side-effects and tolerability profiles, the 
ability to suppress a wider range of mutant clones and reaching a response milestone sooner 
thus avoiding or reducing the risk of relapse. Furthermore third generation drugs are in 
development that show activity against the T315I mutant, which has emerged as a common 
Bcr-Abl mutation based resistance mechanism. However, despite the enormous therapeutic 
benefits of TKIs these drugs do not eradicate leukaemia-initiating stem cells allowing the 
persistence of a reservoir of Bcr-Abl positive stem cells that are potentially responsible for 
disease progression. There is therefore a requirement to elucidate why CML stem cells are 
insensitive to TKIs and to define differences in quiescent versus proliferating CML stem 
cells. Thus current research should lead to development of novel therapeutic strategies that 
may eradicate the stem cell population and finally lead to a cure for CML. It is likely though 
that any new therapeutics for CML will be administered either following or in combination 
with a tyrosine kinase inhibitor. 
9. Acknowledgements 
We would like to acknowledge the Health Research Board and Science Foundation Ireland 
for supporting the research of the Zisterer laboratory on novel therapeutics for the treatment 
of chronic myeloid leukaemia. 
10. References 
Ariyaratana, S. & Loeb, D. M. (2007) The role of the Wilms tumour gene (WT1) in normal 
and malignant haematopoiesis. Expert Reviews in Molecular Medicine, Vol. 9, No. 14 
(May 2007), pp. 1-17, ISSN 1462-3994 
Aswald, J. M., Lipton, J. H., Aswald, S. & Messner, H. A. (2002) Increased IFN-gamma 
synthesis by T cells from patients on imatinib therapy for chronic myeloid 
leukemia. Cytokines Cellular Molecular Therapeutics, Vol. 7, No. 4 (December 2002), 
pp. 143-149, ISSN 1368-4736 
Baccarani, M., Castagnetti, F., Gugliotta, G., Palandri, F. & Soverini, S. (2009) Response 
definitions and European Leukemianet Management recommendations. Best 
Practice & Research Clinical Haematology, Vol. 22, No. 3 (September 2010), pp. 331-
341, ISSN 1532-1924 
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., 
Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., Van Etten, R. A., Donato, N., 
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
16
Hunter, A., Dinsdale, D., Tirro, E., Vigneri, P., Nicotera, P., Dyer, M. J., Holyoake, 
T., Salomoni, P. & Calabretta, B. (2009) Targeting autophagy potentiates tyrosine 
kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, 
including primary CML stem cells. Journal of Clinical Investigation, Vol. 119, No. 5 
(May 2009), pp. 1109-1123, ISSN 1558-8238 
Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N. & Baltimore D. (1986) The 
chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl 
hybrid gene. Science, Vol. 233, No. 4760, (July 1986), pp.212-4, ISSN 0036-8075 
Berke, Z., Andersen, M. H., Pedersen, M., Fugger, L., Zeuthen, J. & Haurum, J. S. (2000) 
Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion 
proteins bind common HLA class I molecules. Leukemia, Vol. 14, No. 3 (March 
2000), pp. 419-426, ISSN 0887-6924 
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. 
L. & Forman, S. J. (2003) Persistence of malignant hematopoietic progenitors in 
chronic myelogenous leukemia patients in complete cytogenetic remission 
following imatinib mesylate treatment. Blood, Vol. 101, No. 12 (June 2003), pp. 4701-
4707, ISSN 0006-4971 
Blake, S. J., Bruce Lyons, A., Fraser, C. K., Hayball, J. D. & Hughes, T. P. (2008) Dasatinib 
suppresses in vitro natural killer cell cytotoxicity. Blood, Vol. 111, No. 8 (April 2008), 
pp. 4415-4416, ISSN 0006-4971 
Blake, S. J., Lyons, A. B. & Hughes, T. P. (2009) Nilotinib inhibits the Src-family kinase LCK 
and T-cell function in vitro. Journal of Cellular & Molecular Medicine, Vol. 13, No. 3 
(March 2009), pp. 599-601, ISSN 1582-4934 
Bixby, D. & Talpaz, M. (2011) Seeking the causes and solutions to imatinib-resistance in 
chronic myeloid leukemia. Leukemia, Vol. 25, No. 1 (January 2011), pp. 7-22, ISSN 
1476-5551 
Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., 
Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S. & Lauria, F. (2005) Effect of a 
p210 multipeptide vaccine associated with imatinib or interferon in patients with 
chronic myeloid leukaemia and persistent residual disease: a multicentre 
observational trial. Lancet, Vol. 365, No. 9560 (February 2005), pp. 657-662, ISSN 
1474-547X 
Boissel, N., Rousselot, P., Raffoux, E., Cayuela, J. M., Soulier, J., Mooney, N., Charron, D., 
Dombret, H., Toubert, A. & Rea, D. (2006) Imatinib mesylate minimally affects Bcr-
Abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell 
expansion despite reciprocal dendritic cell-T cell activation. Journal of Leukocyte 
Biology, Vol. 79, No. 4 (April 2006), pp. 747-756, ISSN 0741-5400 
Bright, S. A., McElligott, A. M., O'Connell, J. W., O'Connor, L., Carroll, P., Campiani, G., 
Deininger, M. W., Conneally, E., Lawler, M., Williams, D. C. & Zisterer, D. M. 
(2010) Novel pyrrolo-1,5-benzoxazepine compounds display significant activity 
against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient 
samples and in vivo. British Journal of Cancer, Vol. 102, No. 10 (May 2010), pp. 1474-
1482, ISSN 1532-1827 
Bright, S. A., Greene, L. M., Greene, T. F., Campiani, G., Butini, S., Brindisi, M., Lawler, M., 
Meegan, M. J., Williams, D. C. & Zisterer, D. M. (2009) The novel pyrrolo-1,5-
benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib 
mesylate) in human chronic myeloid leukaemia cells. Biochemical Pharmacology, Vol. 
77, No. 3 (November 2009), pp. 310-321, ISSN 1873-2968 
www.intechopen.com
 
Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects 
 
17 
Calabretta, B. & Perrotti, D. (2004) The biology of CML blast crisis. Blood, Vol 103, No. 11 
(June 2004), pp. 4010-4022, ISSN 0006-4971 
Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. (2002) Glivec (STI571, 
imatinib), a rationally developed, targeted anticancer drug. Nature reviews. Drug 
discovery, Vol. 1, No. 7 (July 2002), pp. 493-502, ISSN 1474-1776 
Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V., Papadopoulos, E. B. 
& Scheinberg, D. A. (2004) A multivalent Bcr-Abl fusion peptide vaccination trial in 
patients with chronic myeloid leukemia. Blood, Vol. 103, No. 3 (February 2004), 
pp.1037-1042, ISSN 0006-4971 
Chaise, C., Buchan, S. L., Rice, J., Marquet, J., Rouard, H., Kuentz, M., Vittes, G. E., Molinier-
Frenkel, V., Farcet, J. P., Stauss, H. J., Delfau-Larue, M. H. & Stevenson, F. K. (2008) 
DNA vaccination induces WT1-specific T-cell responses with potential clinical 
relevance. Blood, Vol. 112, No. 7 (October 2008), pp. 2956-2964, ISSN 1528-0020 
Chan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. 
M., Jones, J., Lord, J. W., Lu, W. P., Miller, D., Patt, W. C., Smith, B. D., Petillo, P. A., 
Rutkoski, T. J., Telikepalli, H., Vogeti, L., Yao, T., Chun, L., Clark, R., Evangelista, 
P., Gavrilescu, L. C., Lazarides, K., Zaleskas, V. M., Stewart, L. J., Van Etten, R. A. & 
Flynn, D. L. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine 
kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor 
DCC-2036. Cancer Cell, Vol. 19, No. 4 (April 2011), pp. 556-568, ISSN 1878-3686 
Chen, Y., Hu, Y., Zhang, H., Peng, C. & Li, S. (2009) Loss of the Alox5 gene impairs leukemia 
stem cells and prevents chronic myeloid leukemia. Nature Genetics, Vol. 41, No. 7 
(July 2009), pp. 783-792, ISSN 1546-1718 
Cortes, J., O'Brien, S., & Kantarjian, H. (2004) Discontinuation of imatinib therapy after 
achieving a molecular response. Blood, Vol. 104, No. 7 (October 2004), pp. 2204-
2205, ISSN 0006-4971 
Cowan-Jacob, S. W., Guez, V., Fendrich, G., Griffin, J. D., Fabbro, D., Furet, P., Liebetanz, J., 
Mestan, J. & Manley, P. W. (2004) Imatinib (STI571) resistance in chronic 
myelogenous leukemia: molecular basis of the underlying mechanisms and 
potential strategies for treatment. Mini Reviews in Medicinal Chemistry, Vol. 4, No. 3 
(March 2004), pp. 285-299, ISSN 1389-5575 
Danhauser-Riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. (1996) 
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. 
Cancer Research, Vol. 56, No. 15 (August 1996), pp. 3589-3596, ISSN 0008-5472 
Deininger, M. W., Goldman, J. M. & Melo, J. V. (2000) The molecular biology of chronic 
myeloid leukemia. Blood, Vol. 96, No. 10 (November 2000), pp. 3343-3356, ISSN 
0006-4971 
Dierks, C., Beigi, R., Guo, G. R., Zirlik, K., Stegert, M. R., Manley, P., Trussell, C., Schmitt-
Graeff, A., Landwerlin, K., Veelken, H. & Warmuth, M. (2008) Expansion of Bcr-
Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. 
Cancer Cell, Vol. 14, No. 3 (September 2008), pp. 238-249, ISSN 1878-3686 
Dietz, A. B., Souan, L., Knutson, G. J., Bulur, P. A., Litzow, M. R. & Vuk-Pavlovic, S. (2004) 
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type 
hypersensitivity in vivo. Blood, Vol. 104, No. 4 (August 2004), pp. 1094-1099, ISSN 
0006-4971 
Drobyski, W. R., Keever, C. A., Roth, M. S., Koethe, S., Hanson, G., McFadden, P., Gottschall, 
J. L., Ash, R. C., van Tuinen, P., Horowitz, M. M. & et al. (1993) Salvage 
immunotherapy using donor leukocyte infusions as treatment for relapsed chronic 
myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and 
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
18
toxicity of a defined T-cell dose. Blood, Vol. 82, No. 8 (October 1993), pp. 2310-2318, 
ISSN 0006-4971 
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, 
J. & Lydon, N. B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on 
the growth of Bcr-Abl positive cells. Nature Medicine, Vol. 2, No. 5 (May 1996), pp. 
561-566, ISSN 1078-8956 
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., 
Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., 
Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, 
J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, 
A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., 
Letvak, L., and Larson, R. A. (2006) Five-year follow-up of patients receiving 
imatinib for chronic myeloid leukemia. New England Journal of Medicine Vol. 355, 
No. 23 (December 2006), pp. 2408-2417. ISSN 1533-4406 
Eide, C. A., Adrian, L. T., Tyner, J. W., Mac Partlin, M., Anderson, D. J., Wise, S. C., Smith, B. 
D., Petillo, P. A., Flynn, D. L., Deininger, M. W., O'Hare, T. & Druker, B. J. (2011) 
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid 
leukemia mutant BCR-ABL T315I and exhibits a narrow resistance profile. Cancer 
Research, Vol. 71, No. 9 (May 2011), pp. 3189-3195, ISSN 1538-7445 
Essers, M. A., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A. & 
Trumpp, A. (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. 
Nature, Vol. 458, No. 7240 (April 2009), pp. 904-908, ISSN 1476-4687 
Fei, F., Yu, Y., Schmitt, A., Rojewski, M. T., Chen, B., Greiner, J., Gotz, M., Guillaume, P., 
Dohner, H., Bunjes, D. & Schmitt, M. (2008) Dasatinib exerts an 
immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. 
Experimental Hematolology, Vol. 36, No. 10 (October 2008), pp. 1297-1308, ISSN 0301-
472X 
Fiskus, W., Pranpat, M., Bali, P., Balasis, M., Kumaraswamy, S., Boyapalle, S., Rocha, K., Wu, 
J., Giles, F., Manley, P. W., Atadja, P. & Bhalla, K. (2006) Combined effects of novel 
tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 
against Bcr-Abl-expressing human leukemia cells. Blood, Vol. 108, No. 2 (July 2006), 
pp. 645-652, ISSN 0006-4971 
Gannage, M., Abel, M., Michallet, A. S., Delluc, S., Lambert, M., Giraudier, S., Kratzer, R., 
Niedermann, G., Saveanu, L., Guilhot, F., Camoin, L., Varet, B., Buzyn, A. & Caillat-
Zucman, S. (2005) Ex vivo characterization of multiepitopic tumor-specific CD8 T 
cells in patients with chronic myeloid leukemia: implications for vaccine 
development and adoptive cellular immunotherapy. Journal of Immunology, Vol. 
174, No. 12 (June 2005), pp. 8210-8218, ISSN 0022-1767  
Giles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., and Freedman, S. J. (2007) MK-
0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia 
or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, Vol. 109, 
No. 2 (January 2007), pp. 500-502, ISSN 0006-4971 
Gontarewicz, A. & Brummendorf, T. H. (2010) Danusertib (formerly PHA-739358)--a novel 
combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase 
inhibitor. Recent Results Cancer Research, Vol 184, (January 2010), pp. 199-214, ISSN 
0080-0015  
Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N. & Sawyers, C. L. (2002) BCR-ABL point 
mutants isolated from patients with imatinib mesylate-resistant chronic myeloid 
www.intechopen.com
 
Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects 
 
19 
leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock 
protein 90. Blood, Vol. 100, No. 8 (October, 2002), pp. 3041-3044, ISSN 0006-4971 
Gratwohl, A., Hermans, J., Niederwieser, D., Frassoni, F., Arcese, W., Gahrton, G., Bandini, 
G., Carreras, E., Vernant, J. P., Bosi, A., et al. (1993) Bone marrow transplantation 
for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party 
of the European Group for Bone Marrow Transplantation Bone Marrow Transplant, 
Vol. 12, No. 5 (November 1993), pp. 509-516, ISSN 0268-3369 
Greene, L. M., Kelly, L., Onnis, V., Campiani, G., Lawler, M., Williams, D. C. & Zisterer, D. 
M. (2007) STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-
1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive 
and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells. Journal of 
Pharmacology and Experimental Therapeutics, Vol. 321, No. 1 (April 2007), pp. 288-297, 
ISSN 0022-3565 
Heaney, N. B., Pellicano, F., Zhang, B., Crawford, L., Chu, S., Kazmi, S. M., Allan, E. K., 
Jorgensen, H. G., Irvine, A. E., Bhatia, R. & Holyoake, T. L. (2010) Bortezomib 
induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC 
and NOD/SCID repopulating cells. Blood, Vol. 115, No. 11 (March 2010), pp. 2241-
2250, ISSN 1528-0020 
Hehlmann, R. & Saussele, S. (2008) Treatment of chronic myeloid leukemia in blast crisis. 
Haematologica, Vol. 93, No. 12 (December 2008), pp. 1765-1769, ISSN 1592-8721 
Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Muller, M. C., Pletsch, N., 
Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., Hanel, M., Pfirrmann, M., 
Krause, S. W., Nerl, C., Pralle, H., Gratwohl, A., Hossfeld, D. K., Hasford, J., 
Hochhaus, A. & Saussele, S. (2011) Tolerability-adapted imatinib 800 mg/d versus 
400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic 
myeloid leukemia. Journal of Clinical Oncology, Vol. 29, No.12 (April 2011), pp. 1634-
1642, ISSN 1527-7755 
Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. (1999) Isolation of a highly quiescent 
subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood, Vol. 
94, No. 6 (September 1999), pp. 2056-2064, ISSN 0006-4971 
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., 
Early, T. R., Fazal, L., Gill, A. L., Heathcote, M., Maman, S., Matthews, J. E., 
McMenamin, R. L., Navarro, E. F., O'Brien, M. A., O'Reilly, M., Rees, D. C., Reule, 
M., Tisi, D., Williams, G., Vinkovic, M. & Wyatt, P. G. (2009) Fragment-based 
discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with 
potent aurora kinase activity. Journal of Medicinal Chemistry, Vol. 52, No. 2 (January 
2009), pp. 379-388, ISSN 1520-4804 
Hu, Z., Pan, X. F., Wu, F. Q., Ma, L. Y., Liu, D. P., Liu, Y., Feng, T. T., Meng, F. Y., Liu, X. L., 
Jiang, Q. L., Chen, X. Q., Liu, J. L., Liu, P., Chen, Z., Chen, S. J. & Zhou, G. B. (2009) 
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid 
leukemia. PLoS One, Vol 4, No. 7 (July 2009) pp. e6257, ISSN 1932-6203 
Hughes, T. P., Hochhaus, A., Branford, S., Muller, M. C., Kaeda, J. S., Foroni, L., Druker, B. 
J., Guilhot, F., Larson, R. A., O'Brien, S. G., Rudoltz, M. S., Mone, M., Wehrle, E., 
Modur, V., Goldman, J. M. & Radich, J. P. (2010) Long-term prognostic significance 
of early molecular response to imatinib in newly diagnosed chronic myeloid 
leukemia: an analysis from the International Randomized Study of Interferon and 
STI571 (IRIS). Blood, Vol. 116, No. 19 (November 2010), pp. 3758-3765, ISSN 1528-
0020 
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
20
Huntly, B. J., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., Rowan, R., 
Amaral, S., Curley, D., Williams, I. R., Akashi, K. & Gilliland, D. G. (2004) MOZ-
TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed 
murine hematopoietic progenitors. Cancer Cell, Vol. 6, No. 6 (December 2004), pp. 
587-596, ISSN 1535-6108 
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. 
E., Teruya-Feldstein, J. & Pandolfi, P. P. (2008) PML targeting eradicates quiescent 
leukaemia-initiating cells. Nature, Vol. 453, No. 7198 (June 2008), pp. 1072-1078, 
ISSN 1476-4687 
Jagani, Z., Song, K., Kutok, J. L., Dewar, M. R., Melet, A., Santos, T., Grassian, A., Ghaffari, 
S., Wu, C., Yeckes-Rodin, H., Ren, R., Miller, K. & Khosravi-Far, R. (2009) 
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-
induced evasion of apoptosis in part through regulation of forkhead tumor 
suppressors. Cancer Research, Vol. 69, No. 16 (August 2009), pp. 6546-6555, ISSN 
1538-7445 
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, 
Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boque, C., Chuah, C., 
Bleickardt, E., Bradley-Garelik, M. B., Zhu, C., Szatrowski, T., Shapiro, D., & 
Baccarani, M. (2010a) Dasatinib versus imatinib in newly diagnosed chronic-phase 
chronic myeloid leukemia. New England Journal of Medicine, Vol. 362, No. 24 (June 
2010), pp. 2260-2270, ISSN 1533-4406 
Kantarjian, H., le Coutre, P., Cortes, J., Pinilla-Ibarz, J., Nagler, A., Hochhaus, A., Kimura, S. 
& Ottmann, O. (2010b) Phase 1 study of INNO-406, a dual Abl/Lyn kinase 
inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance 
or intolerance. Cancer, Vol. 116, No. 11 (June 2010), pp. 2665-2672, ISSN 0008-5433 
Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, 
S., Pesant, S., Clubb, F. J., Rosenzweig, A., Salomon, R. N., Van Etten, R. A., Alroy, 
J., Durand, J. B. & Force, T. (2006) Cardiotoxicity of the cancer therapeutic agent 
imatinib mesylate. Nature Medicine, Vol. 12, No. 8 (August 2006), pp.908-916, ISSN 
1078-8956 
Kolb, H. J., Schattenberg, A., Goldman, J. M., Hertenstein, B., Jacobsen, N., Arcese, W., 
Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., 
Mittermueller, J., de Witte, T., Holler, E. & Ansari, H. (1995) Graft-versus-leukemia 
effect of donor lymphocyte transfusions in marrow grafted patients. Blood, Vol. 86, 
No. 5 (September 1995), pp 2041-2050, ISSN 0006-4971 
Komatsu, N., Watanabe, T., Uchida, M., Mori, M., Kirito, K., Kikuchi, S., Liu, Q., Tauchi, T., 
Miyazawa, K., Endo, H., Nagai, T. & Ozawa, K. (2003) A member of Forkhead 
transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle 
arrest in BCR-ABL-expressing cells. Journal of Biological Chemistry, Vol. 278, No. 8 
(February 2003), pp. 6411-6419, ISSN 0021-9258 
Kroemer, G. & Levine, B. (2008) Autophagic cell death: the story of a misnomer. Nature 
Reviews in Molecular Cell Biology, Vol 9, No. 12 (December 2008), pp. 1004-1010, 
ISSN 1471-0080 
Kurzrock, R., Gutterman, J. U. & Talpaz, M. (1988) The molecular genetics of Philadelphia 
chromosome-positive leukemias. New England Journal of Medicine, Vol. 319, No. 15 
(October 1988), pp. 990-998, ISSN 0028-4793 
Legros, L., Hayette, S., Nicolini, F. E., Raynaud, S., Chabane, K., Magaud, J. P., Cassuto, J. P., 
and Michallet, M. (2007) BCR-ABL(T315I) transcript disappearance in an imatinib-
www.intechopen.com
 
Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects 
 
21 
resistant CML patient treated with homoharringtonine: a new therapeutic 
challenge? Leukemia, Vol. 21, No.10 (July 2007), pp. 2204-2206, ISSN 0887-6924 
Li, Z., Oka, Y., Tsuboi, A., Masuda, T., Tatsumi, N., Kawakami, M., Fujioka, T., Sakaguchi, 
N., Nakajima, H., Fujiki, F., Udaka, K., Oji, Y., Kawase, I. & Sugiyama, H. (2005) 
WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a 
candidate peptide for the vaccination of HLA-A*0201-positive patients with 
hematopoietic malignancies. International Journal of Hematology, Vol. 82, No. 5 
(December 2005), pp. 458-459, ISSN 0925-5710 
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., 
Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., 
Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, 
S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., & Borzilleri, R. 
M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- 
piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-
354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in 
preclinical assays. Journal of Medicinal Chemistry, Vol. 47, No. 27 (December 2004), 
pp. 6658-6661, ISSN 0022-2623 
Mahon, F. X., Deininger, M. W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M. & 
Melo, J. V. (2000) Selection and characterization of BCR-ABL positive cell lines with 
differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms 
of resistance. Blood, Vol 96, No. 3 (August 2000), pp. 1070-1079. ISSN 0006-4971 
Mannering, S. I., McKenzie, J. L., Fearnley, D. B. & Hart, D. N. (1997) HLA-DR1-restricted 
Bcr-Abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with 
b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. 
Blood, Vol. 90, No. 1 (July 1997), pp. 290-297, ISSN 0006-4971 
Maslak, P. G., Dao, T., Gomez, M., Chanel, S., Packin, J., Korontsvit, T., Zakhaleva, V., 
Pinilla-Ibarz, J., Berman, E. & Scheinberg, D. A. (2008) A pilot vaccination trial of 
synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients 
with minimal disease. Leukemia, Vol. 22, No. 8 (August 2008), pp. 1613-1616, ISSN 
1476-5551 
Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E. & Davis, M. 
M. (2000) Evidence that specific T lymphocytes may participate in the elimination 
of chronic myelogenous leukemia. Nature Medicine, Vol. 6, No. 9 (September 2000), 
pp.1018-1023, ISSN 1078-8956 
Mumprecht, S., Matter, M., Pavelic, V. & Ochsenbein, A. F. (2006) Imatinib mesylate 
selectively impairs expansion of memory cytotoxic T cells without affecting the 
control of primary viral infections. Blood, Vol. 108, No. 10 (November 2006), pp. 
3406-3413, ISSN 0006-4971 
Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., Kondo, Y., Nakao, S., 
Motoyama, N. & Hirao, A. (2010) TGF-beta-FOXO signalling maintains leukaemia-
initiating cells in chronic myeloid leukaemia. Nature, Vol. 463, No. 7281 (February 
2010), pp. 676-680, ISSN 1476-4687 
Nicolini, F. E., Mauro, M. J., Martinelli, G., Kim, D. W., Soverini, S., Muller, M. C., 
Hochhaus, A., Cortes, J., Chuah, C., Dufva, I. H., Apperley, J. F., Yagasaki, F., 
Pearson, J. D., Peter, S., Sanz Rodriguez, C., Preudhomme, C., Giles, F., Goldman, J. 
M. & Zhou, W. (2009) Epidemiologic study on survival of chronic myeloid 
leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I 
mutation. Blood, Vol. 114, No. 26 (December 2009), pp.5271-5278. ISSN 1528-0020 
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
22
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., 
Zhou, T., Huang, W. S., Xu, Q., Metcalf, C. A., 3rd, Tyner, J. W., Loriaux, M. M., 
Corbin, A. S., Wardwell, S., Ning, Y., Keats, J. A., Wang, Y., Sundaramoorthi, R., 
Thomas, M., Zhou, D., Snodgrass, J., Commodore, L., Sawyer, T. K., Dalgarno, D. 
C., Deininger, M. W., Druker, B. J., & Clackson, T. (2009) AP24534, a pan-BCR-ABL 
inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and 
overcomes mutation-based resistance. Cancer Cell, Vol. 16, No. 5 (November 2009), 
pp. 401-412, ISSN 1878-3686 
Oka, Y., Elisseeva, O. A., Tsuboi, A., Ogawa, H., Tamaki, H., Li, H., Oji, Y., Kim, E. H., Soma, 
T., Asada, M., Ueda, K., Maruya, E., Saji, H., Kishimoto, T., Udaka, K. & Sugiyama, 
H. (2000) Human cytotoxic T-lymphocyte responses specific for peptides of the 
wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics, Vol. 51, No. 2 
(February 2000), pp. 99-107, ISSN 0093-7711 
Oka, Y., Tsuboi, A., Taguchi, T., Osaki, T., Kyo, T., Nakajima, H., Elisseeva, O. A., Oji, Y., 
Kawakami, M., Ikegame, K., Hosen, N., Yoshihara, S., Wu, F., Fujiki, F., Murakami, 
M., Masuda, T., Nishida, S., Shirakata, T., Nakatsuka, S., Sasaki, A., Udaka, K., 
Dohy, H., Aozasa, K., Noguchi, S., Kawase, I. & Sugiyama, H. (2004) Induction of 
WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide 
vaccine and the resultant cancer regression. Proceedings National Academy of Sciences 
U.S.A., Vol 101, No. 38 (September 2004), pp. 13885-13890, ISSN 0027-8424 
Olavarria, E., Siddique, S., Griffiths, M. J., Avery, S., Byrne, J. L., Piper, K. P., Lennard, A. L., 
Pallan, L., Arrazi, J. M., Perz, J. B., O'Shea, D., Goldman, J. M., Apperley, J. F. & 
Craddock, C. F. (2007) Posttransplantation imatinib as a strategy to postpone the 
requirement for immunotherapy in patients undergoing reduced-intensity 
allografts for chronic myeloid leukemia. Blood, Vol. 110, No. 13 (December 2007), 
pp. 4614-4617, ISSN 0006-4971 
Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., 
Bronson, R., Aster, J. C., Scott, M. L. & Baltimore, D. (1998) Efficient and rapid 
induction of a chronic myelogenous leukemia-like myeloproliferative disease in 
mice receiving P210 bcr/abl-transduced bone marrow. Blood, Vol. 92, No. 10 
(November 1998), pp. 3780-3792, ISSN 0006-4971 
Pinilla-Ibarz, J., Korontsvit, T., Zakhaleva, V., Roberts, W. & Scheinberg, D. A. (2005) 
Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction 
of heteroclitic human T-cell responses. Haematologica, Vol. 90, No. 10 (October 
2005), pp. 1324-1332, ISSN 1592-8721 
Pinilla-Ibarz, J., Shah, B. & Dubovsky, J. A. (2009) The biological basis for immunotherapy in 
patients with chronic myelogenous leukemia. Cancer Control, Vol. 16, No. 2 (April 
2009), pp. 141-152, ISSN 1526-2359 
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, 
F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Rea, D., Jourdan, E., 
Allard, C., Delmer, A., Rousselot, P., Legros, L., Berger, M., Corm, S., Etienne, G., 
Roche-Lestienne, C., Eclache, V., Mahon, F. X. & Guilhot, F. (2010) Imatinib plus 
peginterferon alfa-2a in chronic myeloid leukemia. New England Journal of Medicine, 
Vol. 363, No. 26 (December 2010), pp. 2511-2521, ISSN 1533-4406 
Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Muller, A., 
Baumgartner, C., Valent, P., Augustin, M., Till, J. H. & Superti-Furga, G. (2009) 
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid 
leukemia cells. Leukemia, Vol. 23, No.3 (March 2009), pp. 477-485, ISSN 1476-5551 
www.intechopen.com
 
Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects 
 
23 
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R. 
& Weissman, I. L. (2003) A role for Wnt signalling in self-renewal of haematopoietic 
stem cells. Nature, Vol. 423, No. 6938 (May 2003), pp. 409-414, ISSN 0028-0836 
Rezvani, K. & Barrett, A. J. (2008) Characterizing and optimizing immune responses to 
leukaemia antigens after allogeneic stem cell transplantation. Best Practice Research 
Clinical Haematology, Vol. 21, No. 3 (September 2008), pp. 437-453, ISSN 1521-6926  
Rezvani, K., Yong, A. S., Mielke, S., Savani, B. N., Musse, L., Superata, J., Jafarpour, B., Boss, 
C. & Barrett, A. J. (2008) Leukemia-associated antigen-specific T-cell responses 
following combined PR1 and WT1 peptide vaccination in patients with myeloid 
malignancies. Blood, Vol. 111, No. 1 (January 2008), pp. 236-242, ISSN 0006-4971 
Rezvani, K., Yong, A. S., Tawab, A., Jafarpour, B., Eniafe, R., Mielke, S., Savani, B. N., 
Keyvanfar, K., Li, Y., Kurlander, R. & Barrett, A. J. (2009) Ex vivo characterization 
of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in 
patients with acute lymphoblastic leukemia and acute and chronic myeloid 
leukemia. Blood, Vol. 113, No. 10 (March 2009), pp. 2245-2255, ISSN 1528-0020 
Rojas, J. M., Knight, K., Wang, L. & Clark, R. E. (2007) Clinical evaluation of BCR-ABL 
peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. 
Leukemia, Vol. 21, No. 11 (November 2007), pp. 2287-2295, ISSN 0887-6924 
Saglio, G., Kim, D. W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, 
R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., 
Haque, A., Larson, R. A., & Kantarjian, H. M. (2010) Nilotinib versus imatinib for 
newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, Vol. 
362, No. 24 (June 2010), pp. 2251-2259, ISSN 1533-4406 
Santaguida, M., Schepers, K., King, B., Sabnis, A. J., Forsberg, E. C., Attema, J. L., Braun, B. S. 
& Passegue, E. (2009) JunB protects against myeloid malignancies by limiting 
hematopoietic stem cell proliferation and differentiation without affecting self-
renewal. Cancer Cell, Vol. 15, No. 4 (April 2009), pp. 341-352, ISSN 1878-3686 
Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D. W., Bunjes, D., Schwerdtfeger, R., Kolb, 
H. J., Ho, A. D., Falge, C., Holler, E., Schlimok, G., Zander, A. R., Arnold, R., Kanz, 
L., Dengler, R., Haferlach, C., Schlegelberger, B., Pfirrmann, M., Muller, M. C., 
Schnittger, S., Leitner, A., Pletsch, N., Hochhaus, A., Hasford, J. & Hehlmann, R. 
(2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic 
myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of 
the randomized German CML Study IV. Blood, Vol. 115, No. 10 (March 2010), pp. 
1880-1885, ISSN 1528-0020 
Savage, D.G., Szydlo, R.M., Chase, A., Apperley, J.F. & Goldman, J.M. (1997) Bone marrow 
transplantation for chronic myeloid leukaemia: the effects of differing criteria for 
defining chronic phase on probabilities of survival and relapse. British Journal of 
haematology, Vol. 99, No. 1, (October 1997), pp. 30-35, ISSN 0007-1048  
Savani, B. N., Montero, A., Kurlander, R., Childs, R., Hensel, N. & Barrett, A. J. (2005) 
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular 
remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow 
Transplant, Vol. 36, No. 11 (December 2005), pp. 1009-1015, ISSN 0268-3369 
Shtivelman, E., Lifshitz, B., Gale, R. P., Roe, B. A. & Canaani, E. (1986) Alternative splicing of 
RNAs transcribed from the human abl gene and from the Bcr-Abl fused gene. Cell, 
Vol. 47, No. 2 (October 1986), pp. 277-284, ISSN 0092-8674 
Tang, R., Faussat, A. M., Majdak, P., Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O. & 
Marie, J. P. (2006) Semisynthetic homoharringtonine induces apoptosis via 
inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-
www.intechopen.com
 
Myeloid Leukemia – Clinical Diagnosis and Treatment 
 
24
regulation in myeloid leukemia cells. Molecular Cancer Therapeutics, Vol. 5, No. 3 
(March, 2006), pp. 723-731, ISSN 1535-7163 
Wang, J. C., Lapidot, T., Cashman, J. D., Doedens, M., Addy, L., Sutherland, D. R., Nayar, R., 
Laraya, P., Minden, M., Keating, A., Eaves, A. C., Eaves, C. J. & Dick, J. E. (1998) 
High level engraftment of NOD/SCID mice by primitive normal and leukemic 
hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. 
Blood, Vol. 91, No. 7 (April, 1998), pp. 2406-2414, ISSN 0006-4971 
Weisberg, E., Manley, P. W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S. W., Ray, A., 
Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, 
G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., 
Gilliland, D. G., & Griffin, J. D. (2005) Characterization of AMN107, a selective 
inhibitor of native and mutant Bcr-Abl. Cancer Cell, Vol.7, No.2 (February 2005), pp. 
129-141, ISSN 1535-6108 
Wilson, M. B., Schreiner, S. J., Choi, H. J., Kamens, J. & Smithgall, T. E. (2002) Selective 
pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-
Abl signal transduction and oncogenesis. Oncogene, Vol. 21, No. 53 (November 
2002), pp. 8075-8088, ISSN 0950-9232 
Yasukawa, M., Ohminami, H., Kaneko, S., Yakushijin, Y., Nishimura, Y., Inokuchi, K., 
Miyakuni, T., Nakao, S., Kishi, K., Kubonishi, I., Dan, K. & Fujita, S. (1998) CD4(+) 
cytotoxic T-cell clones specific for Bcr-Abl b3a2 fusion peptide augment colony 
formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-
restricted manner. Blood, Vol. 92, No. 9 (November 1998), pp. 3355-3361, ISSN 0006-
4971 
Ye, D., Garcia-Manero, G., Kantarjian, H. M., Xiao, L., Vadhan-Raj, S., Fernandez, M. H., 
Nguyen, M. H., Medeiros, L. J. & Bueso-Ramos, C. E. (2009) Analysis of Aurora 
kinase A expression in CD34(+) blast cells isolated from patients with 
myelodysplastic syndromes and acute myeloid leukemia. Journal of 
Hematopathology, Vol. 2, No. 1 (March 2009), pp. 2-8, ISSN 1865-5785 
Zhang, B., Strauss, A. C., Chu, S., Li, M., Ho, Y., Shiang, K. D., Snyder, D. S., Huettner, C. S., 
Shultz, L., Holyoake, T. & Bhatia, R. (2010) Effective targeting of quiescent chronic 
myelogenous leukemia stem cells by histone deacetylase inhibitors in combination 
with imatinib mesylate. Cancer Cell, Vol. 17, No. 5 (May 2010), pp. 427-442, ISSN 
1878-3686 
Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., Lagoo, A. & Reya, T. 
(2007) Loss of beta-catenin impairs the renewal of normal and CML stem cells in 
vivo. Cancer Cell, Vol. 12, No. 6 (December 2007), pp. 528-541, ISSN 1535-6108 
Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., 
Kim, J., Chute, J. P., Rizzieri, D., Munchhof, M., VanArsdale, T., Beachy, P. A. & 
Reya, T. (2009) Hedgehog signalling is essential for maintenance of cancer stem 
cells in myeloid leukaemia. Nature, Vol. 458, No. 7239 (April 2009), pp. 776-779, 
ISSN 1476-4687 
www.intechopen.com
Myeloid Leukemia - Clinical Diagnosis and Treatment
Edited by Dr Steffen Koschmieder
ISBN 978-953-307-886-1
Hard cover, 296 pages
Publisher InTech
Published online 05, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book comprises a series of chapters from experts in the field of diagnosis and treatment of myeloid
leukemias from all over the world, including America, Europe, Africa and Asia. It contains both reviews on
clinical aspects of acute (AML) and chronic myeloid leukemias (CML) and original publications covering
specific clinical aspects of these important diseases. Covering the specifics of myeloid leukemia epidemiology,
diagnosis, risk stratification and management by authors from different parts of the world, this book will be of
interest to experienced hematologists as well as physicians in training and students from all around the globe.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Daniela M. Zisterer (2012). Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects,
Myeloid Leukemia - Clinical Diagnosis and Treatment, Dr Steffen Koschmieder (Ed.), ISBN: 978-953-307-886-
1, InTech, Available from: http://www.intechopen.com/books/myeloid-leukemia-clinical-diagnosis-and-
treatment/treatment-of-chronic-myeloid-leukaemia-current-practice-and-future-prospects
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
